article

Expert view: The future of biologics quality – multiple attribute methodology

Posted: 19 December 2019 | | No comments yet

Characterisation and quality control of proteinbased biotherapeutics has historically been a lengthy and challenging process due to their complexity and inherent heterogeneity.

Sean McCarthy discusses how multiple attribute methodology (MAM) is gaining traction as a novel approach for biologics characterisation.

As analytical approaches and methods have advanced they have been applied with great effect to increase the understanding of product quality attributes (PQAs) and ultimately critical quality attributes (CQAs) to ensure high-quality products that are safe and efficacious. Until recently, mass spectrometry (MS) has been widely used for characterisation efforts; however, as molecules progress through the development and commercialisation process, orthogonal assays have been developed using bridging studies to correlate mass spectrometric results with these assays.











To read this expert view in full, please complete the form below. By clicking submit you confirm that you accept our terms and conditions and privacy policy.


*

*

*

*

*

*

*

*

This content is provided to you for free thanks to the kind support of our sponsor: SCIEX

Send this to a friend